kaiser cover tirzepatide (weight loss) 15 mg/0.5 mL subcutaneous pen injector Recently approved KP Research Bank

FDA approval and indications Tirzepatide was first approved by the FDA in May 2022 as Mounjaro, a once-weekly injectable medication for the treatment of adults with type 2 diabetes

Abstract Introduction The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting

A consultation is needed to determine candidacy

You might be facing a supply shortage or trying to manage the high costs of treatment

Peptide medications are described as sensitive to temperature fluctuations, light exposure and time